Physician profile
Daisy C Hoffert
NPI 1275723660
$1,523.36
in general payments reported to CMS, 2019-2025
12 companies · $1,064 in 2025
The $1,064 reported for 2025 was more than what 90% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.84 · 2022: $31.49 · 2023: $33.95 · 2024: $377 · 2025: $1,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,474.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $379.01 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $313.99 | 2024-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $299.98 | 2022-2025 | |
| Incyte Corporation | $197.28 | 2024-2025 | Opzelura |
| Strata Skin Sciences, INC. | $95.53 | 2024-2025 | Xtrac |
| Lilly USA, LLC | $71.20 | 2025 | Taltz, Ebglyss |
| Genzyme Corporation | $45.63 | 2025 | |
| Janssen Biotech, INC. | $45.50 | 2024 | Tremfya |
| Ucb, INC. | $24.97 | 2025 | Bimzelx |
| Verrica Pharmaceuticals INC. | $19.50 | 2025 | Ycanth |
| Organon LLC | $17.01 | 2025 | Vtama |
| Pfizer INC. | $13.76 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daisy Hoffert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.